Henry Lupin's blog : The PSA Puzzle: Proscar's Shadow on Screening

Screening in the Age of BPH Treatment

Prostate cancer screening remains a cornerstone of men's health, particularly for those over 50. The combination of a Prostate-Specific Antigen (PSA) blood test and a digital rectal examination (DRE) helps us detect potentially life-threatening cancers at an early, more treatable stage. However, as Dr. Evans, a urologist, I know that interpreting these screening tools requires context. Various factors can influence PSA levels, including age, prostate size, inflammation (prostatitis), and crucially, certain medications used to treat Benign Prostatic Hyperplasia (BPH).

Mr. Davies, a patient in his late sixties, perfectly exemplified this complexity. He had been taking Proscar 5mg (finasteride) for several years to manage his significantly enlarged prostate. The medication worked well for his urinary symptoms, and as expected, it had also significantly lowered his PSA levels.

A Subtle Shift, A Cause for Concern

He came in for his annual check-up, reporting stable urinary function – a testament to Proscar's effectiveness for his BPH. We performed the routine screening tests. His digital rectal exam felt largely unchanged, perhaps a subtle firmness on one side, but nothing overtly alarming given his large gland. The key finding was in his bloodwork.

His PSA level was 0.8 ng/mL. On the surface, this looks wonderfully low – well below the traditional thresholds that often trigger concern. However, knowing he was on Proscar changed the entire interpretation.

"Mr. Davies," I began, pulling up his history on the monitor, "your PSA result today is 0.8. Now, remember, Proscar typically cuts the PSA value roughly in half. So, to get an estimate of what your PSA might be without the medication's effect, we need to double this number. That gives us an adjusted estimate of around 1.6 ng/mL."

"That adjusted number itself isn't necessarily alarming," I continued, "but here's the part we need to pay close attention to." I pointed to his previous results. "Last year, your PSA was 0.6, and the year before it was 0.5. This means that while still low, your PSA has shown a definite increase over the past two years. We call this the PSA velocity, or rate of change."

Interpreting Data Under Proscar's Influence

This required careful explanation. "In a man not taking Proscar, a PSA rising from 1.0 to 1.6 over two years might warrant watchful waiting. But because Proscar artificially suppresses the PSA level, any sustained rise, even from a very low baseline, is considered more significant. It suggests something might be stimulating PSA production despite the medication's suppressive effect. That 'something' could potentially be an underlying prostate cancer."

I combined this with the clinical finding. "Added to that, I felt a subtle firmness on the left side during your exam today, which might be new. Taken together – the rising PSA velocity (even though the absolute numbers are low) and the exam finding – it raises enough concern that we shouldn't be falsely reassured by the low 0.8 value alone. Proscar requires us to look deeper."

Navigating the Diagnostic Pathway

We discussed the next steps. "We have a few options," I outlined. "One is to continue monitoring closely, perhaps repeating the PSA sooner than a year. Another is to get more detailed imaging, specifically a prostate MRI, which can sometimes identify suspicious areas within the gland. The third option, given the combination of findings, is to proceed directly to a prostate biopsy."

Mr. Davies, understandably concerned but appreciating the careful explanation, asked, "What do you recommend, Doctor?"

"Given both the PSA trend and the exam finding, I lean towards getting more information before deciding on a biopsy," I advised. "A multi-parametric prostate MRI would be a sensible next step. It can help clarify if there's a specific lesion corresponding to what I felt and guide a potential biopsy more accurately if needed."

He agreed. The subsequent MRI did, in fact, reveal a moderately suspicious lesion (PIRADS 4) in the area where I'd felt the firmness. This provided a clear target.

Confirmation and the Importance of Vigilance

Based on the MRI results, we proceeded with a targeted prostate biopsy. The pathology report confirmed the presence of Gleason score 3+4=7 prostate cancer – a clinically significant but still localized and highly treatable cancer. Mr. Davies chose robotic prostatectomy as his treatment and had an excellent outcome with an undetectable PSA post-operatively.

His case was a textbook example of the challenges and nuances involved in prostate cancer screening for men on 5-alpha-reductase inhibitors like Proscar 5mg. Without understanding Proscar's effect on PSA and interpreting the results accordingly – focusing on the trend (velocity) and correlating with the physical exam – his cancer could easily have been missed or diagnosed later, potentially at a more advanced stage, simply because the absolute PSA number looked reassuringly low.

Reflection: Seeing Through the Shadow

Managing patients on Proscar 5mg requires a specific kind of vigilance. While it’s an excellent medication for treating BPH symptoms and shrinking the prostate, its impact on PSA levels creates a potential "shadow" that can obscure the early signs of prostate cancer if not interpreted correctly. Urologists must mentally double the PSA value, pay meticulous attention to PSA velocity even at low levels, perform careful digital rectal exams, and maintain a lower threshold for further investigation (like MRI or biopsy) compared to men not on the medication. Proscar is a valuable tool, but it demands that we adjust our lens, ensuring we can still detect underlying concerns hidden beneath its beneficial, PSA-lowering effect. It reminds us that interpreting diagnostic tests always requires clinical context, especially when medications alter the baseline.

In: